Iktos Announces Collaboration With Pfizer in AI for Drug Design

Aitechpark04 Mar, 2021Technology

Iktos announced today the application of Iktos Artificial Intelligence technology for de novo design to selected Pfizer small-molecule discovery programs. Over the last few years, phenomenal advances in AI algorithmic development and computational power have enabled innovative approaches in small-molecule drug design. Iktos has been at the forefront of these efforts putting its generative modeling technology at work in several collaborations with pharmaceutical and biotechnology companies. A key aspect of the technology is that exploration of chemical space is performed by generating compounds in silico under the constraints of program endpoints, rather than screening libraries of compounds.